BCHMF (Bachem Holding AG) Research & Development: $12.7 Mil (TTM As of Dec. 2025)


BCHMF Bachem Holding AG BCHMF
91 GF Score
Price $87.34
GF Value $98.06
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Bachem Holding AG Research & Development?

Bachem Holding AG BCHMF 91 Research & Development is $12.7 Mil as of Dec. 2025. GuruFocus rates BCHMF with a GF Score™ of 91/100 and a GF Value™ of $98.06 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bachem Holding AG's Research & Development for the six months ended in Dec. 2025 was $6.9 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $12.7 Mil.

Bachem Holding AG  (OTCPK:BCHMF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bachem Holding AG Research & Development Related Terms

Bachem Holding AG Research & Development Historical Data

* Premium members only.

The historical data trend for Bachem Holding AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bachem Holding AG Research & Development Chart

Bachem Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.14 7.73 12.77 12.76 12.84

Bachem Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.41 7.86 4.88 5.84 6.87
BCHMF
91GF Score
Bachem Holding AG BCHMF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bachem Holding AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $12.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $12.7 Mil mean?
Bachem Holding AG (BCHMF) has a Research & Development of $12.7 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Bachem Holding AG and its competitors.
Is Bachem Holding AG's Research & Development too high?
Bachem Holding AG's current Research & Development is $12.7 Mil. Overall, Bachem Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's Research & Development compare to VRTX and REGN?
Bachem Holding AG's Research & Development of $12.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bachem Holding AG and its competitors. Bachem Holding AG's current Research & Development is $12.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $98.06, compared to a current price of $87.34 — trading 10.9% below its estimated fair value. The current Research & Development is $12.7 Mil. Bachem Holding AG's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current Research & Development is $12.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bachem Holding AG (BCHMF) Overvalued in 2026?

Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued. The current stock price of $87.34 is trading 10.9% below its estimated GF Value™ of $98.06. GuruFocus considers Bachem Holding AG to be Modestly Undervalued.

Key valuation signals for BCHMF:

  • Research & Development: $12.7 Mil
  • GF Value™: $98.06 vs. price of $87.34 (10.9% below fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bachem Holding AG Business Description

Address Hauptstrasse 144, Bubendorf, CHE, 4416
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
91GF Score

Get the complete analysis for BCHMF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$87.34
Price
$98.06
GF Value